Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $37.19 million. The enterprise value is $2.59 million.
Important Dates
The next confirmed earnings date is Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.76 million shares outstanding. The number of shares has decreased by -0.58% in one year.
| Current Share Class | 10.76M |
| Shares Outstanding | 10.76M |
| Shares Change (YoY) | -0.58% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 12.22% |
| Float | 7.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.67, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.67 |
| Quick Ratio | 7.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.82% and return on invested capital (ROIC) is -30.64%.
| Return on Equity (ROE) | -44.82% |
| Return on Assets (ROA) | -28.07% |
| Return on Capital (ROIC) | -30.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$845,128 |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.95% in the last 52 weeks. The beta is 1.57, so Lantern Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +16.95% |
| 50-Day Moving Average | 3.61 |
| 200-Day Moving Average | 5.00 |
| Relative Strength Index (RSI) | 49.37 |
| Average Volume (20 Days) | 37,985 |
Short Selling Information
The latest short interest is 176,913, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 176,913 |
| Short Previous Month | 190,009 |
| Short % of Shares Out | 1.64% |
| Short % of Float | 2.23% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.54M |
| Pretax Income | -17.75M |
| Net Income | -17.75M |
| EBITDA | -19.53M |
| EBIT | -19.54M |
| Earnings Per Share (EPS) | -$1.64 |
Full Income StatementBalance Sheet
The company has $33.26 million in cash and $218,696 in debt, giving a net cash position of $33.04 million or $3.07 per share.
| Cash & Cash Equivalents | 33.26M |
| Total Debt | 218,696 |
| Net Cash | 33.04M |
| Net Cash Per Share | $3.07 |
| Equity (Book Value) | 30.93M |
| Book Value Per Share | 2.87 |
| Working Capital | 30.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.26 million and capital expenditures -$16,342, giving a free cash flow of -$15.27 million.
| Operating Cash Flow | -15.26M |
| Capital Expenditures | -16,342 |
| Free Cash Flow | -15.27M |
| FCF Per Share | -$1.42 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |